Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

January 17, 2024

https://www.globenewswire.com/news-release/2024/01/16/2809854/0/en/Solid-Biosciences-Granted-FDA-Orphan-Drug-Designation-for-Duchenne-Muscular-Dystrophy-Gene-Therapy-Candidate-SGT-003.html

– Patient dosing expected to begin mid-to-late Q1 2024 –

CHARLESTOWN, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has been granted orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for SGT-003, the company’s next-generation Duchenne muscular dystrophy (Duchenne) gene therapy candidate.

Read more at globenewswire.com

Related news for (SLDB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.